A pharmacokinetic study to compare the bioavailability between MK-0663 (etoricoxib ) 120 mg Tablets from Two Different Manufacturing Sites (Frosst Iberica, Spain versus Elkton, VA, USA).

A pharmacokinetic study to compare the bioavailability between MK-0663 (etoricoxib ) 120 mg Tablets from Two Different Manufacturing Sites (Frosst Iberica, Spain versus Elkton, VA, USA). - MK-0663 (CS0177)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON37397

Enrollment

Registered

2012-02-16

Start date

2012-02-23

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthrosis rheumatism

Interventions

The study will start with a screening. A few standard medical assessments will be performed (physical examination, ECG, vital signs). Furthermore a blood and urine sample will be taken for laborator

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male and female, between 18-55 years of age, BMI 18-30.

Exclusion criteria

Exclusion criteria: Clinical significant abnormalities at medical research

Design outcomes

Primary

Measure	Time frame
To determine the relative bioavailability of etoricoxib 120 mg tablets manufactured at Frosst Iberica, Spain and Elkton, VA, USA.	—

Secondary

Measure	Time frame
To evaluate the safety and tolerability of a single dose of 120 mg etoricoxib manufactured at Frosst Iberica, Spain and Elkton, VA, USA, in healthy adults.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)